Related references
Note: Only part of the references are listed.A Prospective, Multicenter Registry Study to Evaluate the Clinical Feasibility of Targeted Axillary Dissection (TAD) in Node-positive Breast Cancer Patients
Sherko Kuemmel et al.
ANNALS OF SURGERY (2022)
Clinical significance of HER2 status in T1bN0 breast cancer: a nationwide study from the Korean Breast Cancer Society
Young-Joon Kang et al.
BREAST CANCER RESEARCH AND TREATMENT (2021)
The Financial Impact on Reimbursement of Moderately Hypofractionated Postoperative Radiation Therapy for Breast Cancer: An International Consortium Report
G. N. Marta et al.
CLINICAL ONCOLOGY (2021)
Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group
Torsten O. Nielsen et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
Impact of guideline changes on adoption of hypofractionation and breast cancer patient characteristics in the randomized controlled HYPOSIB trial
David Krug et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2021)
Moderate hypofractionation remains the standard of care for whole-breast radiotherapy in breast cancer: Considerations regarding FAST and FAST-Forward
David Krug et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2021)
Evaluation of the efficacy of Trastuzumab in patients with HER2 positive small (pT1mi/a) breast cancers. A multicenter retrospective study on 100 patients
A. Villasco et al.
BREAST (2021)
Commercially Available Gene Expression Assays as Predictive Tools for Adjuvant Radiotherapy? A Critical Review
David Krug et al.
BREAST CARE (2020)
DEGRO practical guideline for partial-breast irradiation
V. Strnad et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2020)
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial
Adrian Murray Brunt et al.
LANCET (2020)
Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial
Jayant S. Vaidya et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
COOLHAIR: a prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer
Katharina Smetanay et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer
Peter A. Fasching et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial
Shu-Lian Wang et al.
LANCET ONCOLOGY (2019)
Prophylactic irradiation to the contralateral breast for BRCA mutation carriers with early-stage breast cancer
E. Evron et al.
ANNALS OF ONCOLOGY (2019)
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
G. von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Scalp Hypothermia for Preventing Alopecia During Chemotherapy. A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Hope S. Rugo et al.
CLINICAL BREAST CANCER (2018)
FAST Phase III RCT of Radiotherapy Hypofractionation for Treatment of Early Breast Cancer: 10-Year Results (CRUKE/04/015)
A. M. Brunt et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)
Restricted Axillary Staging in Clinically and Sonographically Node-Negative Early Invasive Breast Cancer (c/iT1-2) in the Context of Breast Conserving Therapy: First Results Following Commencement of the Intergroup-Sentinel-Mamma (INSEMA) Trial
T. Reimer et al.
GEBURTSHILFE UND FRAUENHEILKUNDE (2017)
Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer The SCALP Randomized Clinical Trial
Julie Nangia et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis The ACOSOG Z0011 (Alliance) Randomized Clinical Trial
Armando E. Giuliano et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection
Abigail S. Caudle et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
F. Cardoso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy Incorporation of Prognostic Biologic Factors Into Staging After Treatment
Elizabeth A. Mittendorf et al.
JAMA ONCOLOGY (2016)
Vaginal estrogens and risk of recurrence or death in women treated for estrogen receptor positive breast cancer
S. Cold et al.
EUROPEAN JOURNAL OF CANCER (2015)
RTOG 9804: A Prospective Randomized Trial for Good-Risk Ductal Carcinoma In Situ Comparing Radiotherapy With Observation
Beryl McCormick et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial
Jayant S. Vaidya et al.
LANCET (2014)
Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial
Mila Donker et al.
LANCET ONCOLOGY (2014)
Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes
G. Cancello et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients
Folkward G. Wiesner et al.
BREAST (2009)
High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2-Positive, Node-Negative Tumors 1 cm or Smaller
Ana M. Gonzalez-Angulo et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy
Jacqueline S. Jeruss et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Share Paper
